0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Long-term Follow-up of a Child Treated With Efalizumab for Atopic Dermatitis

Elaine C. Siegfried, MD
Arch Dermatol. 2007;143(8):1073-1087. doi:10.1001/archderm.143.8.1077.
Text Size: A A A
Published online

Extract

I appreciate the observations and comments made by Rapaport1 in the February issue of the Archives and agree that a subset of patients with chronic eczema experience corticosteroid dependence and rebound flare. This is probably more common in adults, especially among those who have been treated with long-term topical corticosteroids on the face and groin. Another subset of patients with eczema have severe atopic dermatitis that does not reliably respond to any of the “panoply” of other described options.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.

In September 2005, excellent clearing of eczema is evident after 3 months of efalizumab treatment.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

In July 2006, sustained clearing of eczema is seen after 18 months of efalizumab therapy.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

In September 2005, minimal scalp hair regrowth had occurred after 3 months of efalizumab treatment.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

In July 2006, substantial and sustained regrowth of scalp hair was apparent after 18 months of efalizumab therapy.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

46 Views
1 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();